Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

RNA Interference Technology Market - Global Forecast 2026-2032 | AI-Enabled Discovery and Extrahepatic Delivery Drive 12.96% CAGR and USD 8.26 Billion Opportunity

globenewswire.com
ALNY Alnylam Pharmaceuticals is mentioned as a key player in the RNAi therapeutics space, with its approved siRNA drugs demonstrating clinical potential. The company's focus on durable gene silencing and infrequent dosing aligns with market drivers. ARCT Arcturus Therapeutics is listed as a company in the RNAi space. The article highlights advancements in delivery methods like lipid nanoparticles, which Arcturus utilizes, suggesting a positive outlook for companies innovating in this area. ARWR Arrowhead Pharmaceuticals is identified as a company involved in RNAi technology. The article's focus on the growth of RNAi therapeutics and the importance of delivery methods suggests a positive environment for companies like Arrowhead. BNTX BioNTech SE is listed among companies in the RNAi space. While the article discusses the broader RNAi market, it doesn't provide specific details on BioNTech's current performance or future prospects within this context. INTC Intellia Therapeutics is listed as a participant in the RNAi technology market. The article's positive outlook on the growth and therapeutic applications of RNAi suggests a favorable environment for companies like Intellia. IONS Ionis Pharmaceuticals is mentioned as a company in the RNAi space. The article's discussion on the progression of RNAi from discovery to approved therapeutics and its application in various diseases supports a positive sentiment for Ionis. MRNA Moderna Inc is listed among companies in the RNAi space. The article focuses on the RNAi market's growth and technological advancements, but does not provide specific sentiment or detailed information regarding Moderna's current position or performance. SRPT Sarepta Therapeutics is listed as a company involved in RNAi technology. The article's emphasis on the expanding therapeutic applications of RNAi, including rare diseases, aligns with Sarepta's focus, suggesting a positive outlook. WVE Wave Life Sciences is mentioned as a company in the RNAi technology sector. The article's focus on advancements in delivery methods and the growing market for RNAi therapeutics indicates a positive outlook for companies like Wave Life Sciences.

RNA Interference Technology Market - Global Forecast 2026-2032 | AI-Enabled Discovery and Extrahepatic Delivery Drive 12.96% CAGR and USD 8.26 Billion Opportunity Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Technology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The RNA Interference Technology Market research report provides a comprehensive assessment of the technologies, therapeutic applications, competitive developments, and regional dynamics shaping this rapidly expanding field. The market is projected to reach USD 3.95 billion in 2026 and grow at a CAGR of 12.96% to USD 8.26 billion by 2032.

Market Overview

RNA interference (RNAi) is a validated gene-silencing platform that uses small interfering RNA, microRNA modulation, and related double-stranded RNA approaches to reduce disease-driving messenger RNA before harmful proteins are produced. The field has progressed from discovery biology to approved therapeutics, functional genomics, agricultural biotechnology, and precision medicine.

Commercial momentum is supported by approved siRNA drugs, including patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran. These therapies demonstrate RNAi's clinical potential across rare diseases, cardiometabolic disorders, and renal, metabolic, and liver-targeted indications. The market outlook gives decision-makers a practical foundation for evaluating investment priorities, development pipelines, and market-entry opportunities.

Transformative Shifts in the RNAi Landscape

RNAi development is expanding beyond specialized rare-disease programs into chronic and high-burden conditions. Key areas of opportunity include:

Durable gene silencing, infrequent dosing, and target specificity strengthen RNAi's value proposition relative to conventional small molecules and monoclonal antibodies. Delivery remains the most important competitive frontier, led by GalNAc-siRNA conjugates for hepatocyte targeting and lipid nanoparticles for broader tissue access. Extrahepatic ligands, inhaled delivery, intrathecal administration, intravitreal delivery, and other localized approaches are also expanding the addressable market.

Regulatory expectations surrounding off-target effects, immunogenicity, biodistribution, drug interactions, manufacturing controls, and long-term safety make platform quality a critical differentiator.

Artificial Intelligence in RNAi Development

Artificial intelligence is accelerating target prioritization, siRNA sequence design, off-target prediction, toxicity screening, and delivery formulation optimization. Machine learning models using transcriptomic, proteomic, genomic, structural, and clinical data can reduce the number of low-probability candidates entering expensive laboratory validation.

AI also supports biomarker discovery, patient segmentation, trial enrichment, and real-world evidence analysis. Experimental confirmation remains essential, with successful programs requiring reproducible pharmacokinetic, pharmacodynamic, manufacturing, preclinical, and clinical evidence. These insights support risk mitigation by helping organizations distinguish promising platform capabilities from approaches requiring further validation.

Regional and Economic Group Insights

G7 markets remain central to commercialization due to mature regulation, reimbursement systems, intellectual property protection, and advanced manufacturing standards. BRICS, ASEAN, and GCC markets offer strategic growth potential through large patient populations, expanding research activity, manufacturing investment, and national precision medicine programs. Country-level comparisons enable more informed regional partnerships and market-access planning.

Strategic Priorities for Industry Leaders

Key Takeaways from This Report

Key Attributes:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. RNA Interference Technology Market, by Molecule Type

7.1. Introduction

7.2. MicroRNA (miRNA)

7.3. Short Hairpin RNA (shRNA)

7.3.1. Non-Viral Delivery shRNA

7.3.2. Viral Delivery shRNA

7.4. Small Interfering RNA (siRNA)

7.4.1. Conjugated siRNA

7.4.2. Non-Conjugated siRNA

8. RNA Interference Technology Market, by Route Of Administration

8.1. Introduction

8.2. Intramuscular (IM) Injection

8.3. Intrathecal (IT) Administration

8.4. Intravenous (IV) Injection

9. RNA Interference Technology Market, by Delivery Method

9.1. Introduction

9.2. Direct Naked RNAi Delivery

9.3. Exosome-Based RNAi Therapy

9.4. Nanoparticle-Based Delivery

9.5. Viral Vector-Based Delivery

10. RNA Interference Technology Market, by Application

10.1. Introduction

10.2. Drug Discovery

10.2.1. Lead Optimization

10.2.2. Target Identification

10.3. Research & Development

10.3.1. Gene Function Studies

10.3.2. Pathway Analysis

10.4. Therapeutics

11. RNA Interference Technology Market, by End-User

11.1. Introduction

11.2. Contract Research Organizations

11.3. Hospitals & Clinics

11.4. Pharmaceutical & Biotechnology Companies

12. RNA Interference Technology Market, by Region

12.1. Introduction

12.2. Asia-Pacific

12.3. Europe

12.4. North America

12.5. Latin America

12.6. Africa

12.7. Middle East

13. RNA Interference Technology Market, by Group

13.1. Introduction

13.2. NATO

13.3. G7

13.4. European Union

13.5. BRICS

13.6. ASEAN

13.7. GCC

14. RNA Interference Technology Market, by Country

14.1. Introduction

14.2. United States

14.3. China

14.4. Germany

14.5. Japan

14.6. India

14.7. United Kingdom

14.8. France

14.9. Canada

14.10. Italy

14.11. Australia

14.12. South Korea

14.13. Brazil

14.14. Mexico

14.15. Russia

14.16. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025

15.2. Market Concentration Analysis, 2025

15.2.1. Concentration Ratio (CR)

15.2.2. Herfindahl Hirschman Index (HHI)

15.3. Recent Developments & Impact Analysis, 2025

15.4. Product Portfolio Analysis, 2025

15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. ADARx Pharmaceuticals Inc

16.2. Alnylam Pharmaceuticals Inc

16.3. Arbutus Biopharma Corporation

16.4. Arcturus Therapeutics Holdings Inc

16.5. Arrowhead Pharmaceuticals Inc

16.6. AstraZeneca PLC

16.7. Avidity Biosciences Inc

16.8. Benitec Biopharma Inc

16.9. BioNTech SE

16.10. City Therapeutics Inc

16.11. Genevant Sciences Ltd

16.12. Intellia Therapeutics Inc

16.13. Ionis Pharmaceuticals Inc

16.14. Moderna Inc

16.15. Novartis AG

16.16. Novo Nordisk A/S

16.17. OliX Pharmaceuticals Inc

16.18. Phio Pharmaceuticals Corp

16.19. ProQR Therapeutics NV

16.20. Roche Holding AG

16.21. Sanofi SA

16.22. Sarepta Therapeutics Inc

16.23. Silence Therapeutics PLC

16.24. Sirnaomics Inc

16.25. Suzhou Ribo Life Science Co., Ltd

16.26. Vir Biotechnology Inc

16.27. Wave Life Sciences Ltd

17. Key Experts

List of Figures [21]

List of Tables [323]

For more information about this report visit https://www.researchandmarkets.com/r/dy83cj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.